EXOZYMES INC. just filed for an IPO. The Monrovia, CA-based synthetic biochemical company (formerly Invizyne, ticker IZTC→EXOZ) is developing a cell-free, AI-enhanced enzyme biomanufacturing platform

EXOZYMES is pre-revenue with no commercialized products — its tech has only produced at lab scale. No assurance of commercially viable products or future profitability. Limited operating history as a development-stage company. Cash is the story: ~$5.7M on hand as of June 30, 2026, a $2.9M net loss, and a going concern qualification. Management flags working capital insufficient for twelve months with no committed financing. It will need additional capital after the offering. Some offsets: ~$5.9M net raised in a June 2026 offering, a $50M shelf registration, and non-dilutive grants — a $3M share of a $9.2M NSF CFIRE award (July 2025) and a $283,805 NIH BioClick grant (March 2025). Bottom line: a cash-constrained, pre-revenue story with a going concern flag, a ~12-24 month runway, and insiders/founders reportedly holding over 68% of shares (limited float). In a selective biotech IPO market favoring later-stage, data-rich names, this is a high-risk specul...

EXOZYMES is pre-revenue with no commercialized products — its tech has only produced at lab scale. No assurance of commercially viable products or future profitability. Limited operating history as a